Literature DB >> 25460579

Serotonin (5-HT) inhibits Factor XIII-A-mediated plasma fibronectin matrix assembly and crosslinking in osteoblast cultures via direct competition with transamidation.

Cui Cui1, Mari T Kaartinen2.   

Abstract

Serotonin (5-HT)--a monoamine with a variety of physiological functions--has recently emerged as a major regulator of bone mass. 5-HT is synthesized in the brain and the gut, and gut-derived 5-HT contributes to circulating 5-HT levels and is a negative modulator of bone mass and quality. 5-HT's negative effects on the skeleton are considered to be mediated via its receptors and transporter in osteoblasts and osteoclasts; however, 5-HT can also incorporate covalently into proteins via a transglutaminase-mediated serotonylation reaction, which in turn can alter protein function. Plasma fibronectin (pFN)--a major component of the bone extracellular matrix that regulates bone matrix quality in vivo--is a major transglutaminase substrate in bone and in osteoblast cultures. We have recently demonstrated that pFN assembly into osteoblast culture matrix requires a Factor XIII-A (FXIII-A) transglutaminase-mediated crosslinking step that regulates both quantity and quality of type I collagen matrix in vitro. In this study, we show that 5-HT interferes with pFN assembly into the extracellular matrix in osteoblast cultures, which in turn has major consequences on matrix assembly and mineralization. 5-HT treatment of MC3T3-E1 osteoblast cultures dramatically decreased both pFN fibrillogenesis as analyzed by immunofluorescence microscopy and pFN levels in DOC-soluble and DOC-insoluble matrix fractions. This was accompanied by an increase in pFN levels in the culture media. Analysis of the media showed covalent incorporation of 5-HT into pFN. Minor co-localization of pFN with 5-HT was also seen in extracellular fibrils. 5-HT also showed co-localization with FXIII-A on the cell surface and inhibited its transamidation activity directly. 5-HT treatment of osteoblast cultures resulted in a discontinuous pFN matrix and impaired type I collagen deposition, decreased alkaline phosphatase and lysyl oxidase activity, and delayed mineralization of the cultures. Addition of excess exogenous pFN to cultures treated with 5-HT resulted in a significant rescue of pFN fibrillogenesis as well as type I collagen deposition and mineralization. In summary, our study presents a novel mechanism on how increased peripheral extracellular 5-HT levels might contribute to the weakening of bone by directly affecting the stabilization of extracellular matrix networks.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-HT; Extracellular matrix; Factor XIII-A transglutaminase; Osteoblast; Plasma fibronectin; Serotonylation

Mesh:

Substances:

Year:  2014        PMID: 25460579     DOI: 10.1016/j.bone.2014.11.008

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  3 in total

Review 1.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

2.  Transglutaminase in Receptor and Neurotransmitter-Regulated Functions.

Authors:  Nancy A Muma
Journal:  Med One       Date:  2018-12-05

Review 3.  Relationships between Bone Turnover and Energy Metabolism.

Authors:  Tânia A P Fernandes; Luísa M L Gonçalves; José A A Brito
Journal:  J Diabetes Res       Date:  2017-06-11       Impact factor: 4.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.